ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

eGenesis launches to overhaul transplants

by Lisa M. Jarvis
March 20, 2017 | APPEARED IN VOLUME 95, ISSUE 12

Xenotransplantation-focused eGenesis has secured $38 million in its first round of financing. The biotech firm plans to use the gene-editing technology CRISPR to engineer pig cells to grow human-transplantable cells, tissues, and organs. eGenesis was founded by renowned Harvard Medical School geneticist George Church and his former postdoctoral researcher Luhan Yang, who developed a way to use CRISPR to get rid of pathogenic factors in pig cells. Yang now serves as eGenesis’s chief scientific officer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment